Relic Technologies Reports FY26 Standalone Profit
Relic Technologies announced its audited financial results for FY26, reporting a standalone net profit of ₹54.20 lakh compared to a net loss in the previous year. However, the consolidated net loss widened to ₹694.49 lakh. Total standalone income decreased due to nil revenue from operations, while consolidated income increased.

*this image is generated using AI for illustrative purposes only.
Relic Technologies has announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a turnaround in its standalone performance for the fiscal year, while its consolidated results reflected a wider net loss.
Standalone Financial Performance
For the financial year ended March 31, 2026, the company reported a standalone net profit of ₹54.20 lakh, a reversal from the net loss of ₹171.87 lakh recorded in the previous year. Total standalone income for the year stood at ₹130.18 lakh, down from ₹176.35 lakh in FY25, primarily due to a lack of revenue from operations which was nil compared to ₹166.32 lakh in the prior year. Other income increased to ₹130.18 lakh from ₹10.03 lakh.
On a quarterly basis, the standalone net profit for Q4 FY26 was ₹9.49 lakh, compared to a net loss of ₹24.38 lakh in the same quarter of the previous year. Total expenses for the year reduced to ₹70.95 lakh from ₹346.49 lakh in FY25.
Consolidated Financial Performance
The consolidated financial results for the group, which includes subsidiaries Relic Pharma Limited and Truhealthy Wellness Private Limited, showed a net loss of ₹694.49 lakh for FY26, compared to a net loss of ₹148.74 lakh in the previous year. Total consolidated income for the year increased to ₹341.45 lakh from ₹204.51 lakh. Revenue from operations rose to ₹267.08 lakh from ₹197.59 lakh.
For the quarter ended March 31, 2026, the consolidated net loss was ₹293.70 lakh. The company noted that it reversed deferred tax assets created on carried forward losses during the quarter.
| Metric | Standalone FY26 (₹ In Lakhs) | Standalone FY25 (₹ In Lakhs) | Consolidated FY26 (₹ In Lakhs) | Consolidated FY25 (₹ In Lakhs) |
|---|---|---|---|---|
| Total Income | 130.18 | 176.35 | 341.45 | 204.51 |
| Total Expenses | 70.95 | 346.49 | 798.37 | 351.51 |
| Net Profit/(Loss) | 54.20 | (171.87) | (694.49) | (148.74) |
| Earnings Per Share (Basic) | 1.03 | (4.77) | (13.19) | (4.13) |
Key Financial Highlights
The board approved the audited standalone and consolidated financial results along with the auditors' report. D. Kothary & Co., Chartered Accountants, audited the results and issued an unmodified opinion. The paid-up equity share capital of the company increased to ₹559.12 lakh as of March 31, 2026, from ₹360.00 lakh in the previous year, following the issue of equity shares at a premium.
The company's net cash and cash equivalents decreased significantly in the standalone statement to ₹38.48 lakh as of March 31, 2026, from ₹703.76 lakh at the end of the previous year, largely due to investing and financing activities. In the consolidated statement, cash and cash equivalents stood at ₹70.05 lakh compared to ₹709.79 lakh in the prior year.
Historical Stock Returns for Relic Technologies
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -6.04% | +1.14% | +3.06% | -5.41% | -1.80% | +446.87% |
How will Relic Technologies rebuild its standalone revenue from operations, given that it reported nil revenue in FY26 while relying entirely on other income for profitability?
What is the strategic roadmap for subsidiaries Relic Pharma Limited and Truhealthy Wellness Private Limited to reduce the consolidated net loss, which widened nearly five-fold to ₹694.49 lakh in FY26?
With cash and cash equivalents declining sharply from ₹703.76 lakh to ₹38.48 lakh on a standalone basis, how does the company plan to manage its liquidity and fund future operations?

































